Vedolizumab in the treatment of chronic, antibiotic‐dependent or refractory pouchitis

The most common complication after ileal pouch anal anastomosis in up to 50% of patients is an acute pouchitis. The majority of patients respond to antibiotic treatment. However, 10%‐15% develops chronic antibiotic‐dependent or refractory pouchitis which is usually hard to treat.

[1]  V. Tahan,et al.  Successful treatment of chronic refractory pouchitis with vedolizumab , 2017, International Journal of Colorectal Disease.

[2]  A. Amiot,et al.  One‐year effectiveness and safety of vedolizumab therapy for inflammatory bowel disease: a prospective multicentre cohort study , 2017, Alimentary pharmacology & therapeutics.

[3]  S. Travis,et al.  Systematic review: the safety of vedolizumab for the treatment of inflammatory bowel disease , 2017, Alimentary pharmacology & therapeutics.

[4]  S. Schreiber,et al.  Combination therapy with vedolizumab and etanercept in a patient with pouchitis and spondylarthritis , 2017, BMJ open gastroenterology.

[5]  M. Goetz,et al.  Successful treatment of pouchitis with Vedolizumab, but not fecal microbiota transfer (FMT), after proctocolectomy in ulcerative colitis , 2017, International Journal of Colorectal Disease.

[6]  D. Rubin,et al.  Effects of vedolizumab on health‐related quality of life in patients with ulcerative colitis: results from the randomised GEMINI 1 trial , 2016, Alimentary pharmacology & therapeutics.

[7]  B. Shen,et al.  Efficacy of Vedolizumab in Patients with Antibiotic and Anti-tumor Necrosis Alpha Refractory Pouchitis. , 2017, Inflammatory bowel diseases.

[8]  J. Hampe,et al.  Vedolizumab provides clinical benefit over 1 year in patients with active inflammatory bowel disease – a prospective multicenter observational study , 2016, Alimentary pharmacology & therapeutics.

[9]  Siddharth Singh,et al.  Treatment and prevention of pouchitis after ileal pouch-anal anastomosis for chronic ulcerative colitis. , 2019, The Cochrane database of systematic reviews.

[10]  C. Calabrese,et al.  The therapeutic potential of antibiotics and probiotics in the treatment of pouchitis , 2015, Expert review of gastroenterology & hepatology.

[11]  A. Ford,et al.  Systematic review and meta‐analysis: opportunistic infections and malignancies during treatment with anti‐integrin antibodies in inflammatory bowel disease , 2015, Alimentary pharmacology & therapeutics.

[12]  G. Hajishengallis,et al.  Leukocyte integrins: role in leukocyte recruitment and as therapeutic targets in inflammatory disease. , 2015, Pharmacology & therapeutics.

[13]  Takanori Kanai,et al.  The gut microbiota and inflammatory bowel disease , 2014, Seminars in Immunopathology.

[14]  Elena A. Manilich,et al.  Ileal Pouch Anal Anastomosis: Analysis of Outcome and Quality of Life in 3707 Patients , 2013, Annals of surgery.

[15]  J. Gordillo,et al.  Efficacy of adalimumab rescue therapy in patients with chronic refractory pouchitis previously treated with infliximab: a case series , 2012, European journal of gastroenterology & hepatology.

[16]  J. Gordillo,et al.  Efficacy of infliximab rescue therapy in patients with chronic refractory pouchitis: A multicenter study , 2011, Inflammatory bowel diseases.

[17]  O. Dewit,et al.  Efficacy of infliximab in refractory pouchitis and Crohn's disease‐related complications of the pouch: A Belgian case series , 2010, Inflammatory bowel diseases.

[18]  G. Liguori,et al.  Short‐term treatment with infliximab in chronic refractory pouchitis and ileitis , 2008, Alimentary pharmacology & therapeutics.

[19]  I. Zabalza Estévez,et al.  [Oral budesonide in the treatment of chronic refractory pouchitis]. , 2008, Gastroenterologia y hepatologia.

[20]  V. Fazio,et al.  Combined Ciprofloxacin and Tinidazole Therapy in the Treatment of Chronic Refractory Pouchitis , 2007, Diseases of the colon and rectum.

[21]  P. Gionchetti,et al.  VSL#3: an analysis of basic and clinical contributions in probiotic therapeutics. , 2005, Gastroenterology clinics of North America.

[22]  S. Leveson,et al.  Rifaximin‐ciprofloxacin combination therapy is effective in chronic active refractory pouchitis , 2005, Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland.

[23]  J. Achkar,et al.  Comprehensive Evaluation of Inflammatory and Noninflammatory Sequelae of Ileal Pouch-Anal Anastomoses , 2005, The American Journal of Gastroenterology.

[24]  M. V. M. Frcs,et al.  Double-blind crossover trial of metronidazole versus placebo in chronic unremitting pouchitis , 2005, Digestive Diseases and Sciences.

[25]  R Balfour Sartor,et al.  Therapeutic manipulation of the enteric microflora in inflammatory bowel diseases: antibiotics, probiotics, and prebiotics. , 2004, Gastroenterology.

[26]  P. Miner,et al.  An enema formulation of alicaforsen, an antisense inhibitor of intercellular adhesion molecule‐1, in the treatment of chronic, unremitting pouchitis , 2004, Alimentary pharmacology & therapeutics.

[27]  P. Brigidi,et al.  Prophylaxis of pouchitis onset with probiotic therapy: A double‐blind, placebo‐controlled trial , 2000, Gastroenterology.

[28]  P. Gionchetti,et al.  Treatment of mild to moderate ulcerative colitis and pouchitis , 2002, Alimentary pharmacology & therapeutics.

[29]  M. Kamm,et al.  Four‐week open‐label trial of metronidazole and ciprofloxacin for the treatment of recurrent or refractory pouchitis , 2002, Alimentary pharmacology & therapeutics.

[30]  J. Bai,et al.  Budesonide enema in pouchitis—a double‐blind, double‐dummy, controlled trial , 2002, Alimentary pharmacology & therapeutics.

[31]  J. Achkar,et al.  A Randomized Clinical Trial of Ciprofloxacin and Metronidazole to Treat Acute Pouchitis , 2001, Inflammatory bowel diseases.

[32]  J. Achkar,et al.  Endoscopic and histologic evaluation together with symptom assessment are required to diagnose pouchitis. , 2001, Gastroenterology.

[33]  R. Thirlby,et al.  Risk Factors and True Incidence of Pouchitis in Patients after Ileal Pouch–Anal Anastomoses , 2000, World Journal of Surgery.

[34]  P. Brigidi,et al.  Antibiotic combination therapy in patients with chronic, treatment‐resistant pouchitis , 1999, Alimentary pharmacology & therapeutics.

[35]  R. Farouk,et al.  J ileal pouch–anal anastomosis for chronic ulcerative colitis: complications and long‐term outcome in 1310 patients , 1998, The British journal of surgery.

[36]  A. Lazenby,et al.  Preoperative terminal ileal and colonic resection histopathology predicts risk of pouchitis in patients after ileoanal pull-through procedure. , 1998, Annals of surgery.

[37]  W. Sandborn,et al.  Bismuth carbomer foam enemas for active chronic pouchitis: a randomized, double‐blind, placebo‐controlled trial , 1997, Alimentary pharmacology & therapeutics.

[38]  P. Sagar,et al.  Ileo-anal pouch function and dysfunction. , 1997, Digestive diseases.

[39]  M. Molinari,et al.  Prospective study of the incidence, timing and treatment of pouchitis in 104 consecutive patients after restorative proctocolectomy. , 1996, Archives of surgery.

[40]  N. Mortensen,et al.  Smoking may prevent pouchitis in patients with restorative proctocolectomy for ulcerative colitis. , 1996, Gut.

[41]  J. Church,et al.  IIeal Pouch‐Anal Anastomoses Complications and Function in 1005 Patients , 1995, Annals of surgery.

[42]  W. Sandborn.  Pouchitis following heal pouch-anal anastomosis: Definition, pathogenesis, and treatment , 1994 .

[43]  W. Sandborn.  Pouchitis following ileal pouch-anal anastomosis: definition, pathogenesis, and treatment. , 1994, Gastroenterology.

[44]  J. Murray,et al.  Long-term results of the ileoanal pouch procedure. , 1993, Archives of surgery.

[45]  D. Jewell,et al.  Cyclosporin A retention enemas in refractory distal ulcerative colitis and 'pouchitis'. , 1993, Scandinavian journal of gastroenterology.

[46]  D. Rothenberger,et al.  [Etiology of "pouchitis"]. , 1993, Annales de chirurgie.

[47]  L. Braslow.  Pouchitis and extraintestinal manifestations of inflammatory bowel disease after ileal pouch-anal anastomosis. , 1991, Annals of surgery.